Laura Moretti
0000-0003-0488-0140
2 papers found
Refreshing results…
ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
Missing publications? Search for publications with a matching author name.